Shortly after its launch in 2004, NittoPhase™ became the leading solid support in the therapeutic oligonucleotide market, with established results in commercial synthesis up to 600 mmol scale. With the introduction of NittoPhase™ HL, high loading support, Kinovate has redefined the boundaries of solid phase oligo synthesis.
The groundbreaking high loading capacity of NittoPhase™ HL enables greater synthesis scales per column volume with superior yields and purities that customers have come to expect from NittoPhase™, allowing significant savings in overall synthesis costs.
©KINOVATE LIFE SCIENCES. 2024 All rights reserved.